Hulio®

INN: adalimumab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Biosimilar

Delivery Route

Subcutaneous Injection

Health Canada Approval

2020

Storage

Refrigerate between 2 and 8°C, do not freeze, keep in original carton to protect from light, may be stored at room temperature (up to 25°C) for a single period of up to 56 days.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

No pattern of major birth defects has been observed; infants may be at increased risk for infection.

Breastfeeding Indication

Low exposure levels due to large molecule size and degradation by GI tract.

Pediatric Indication

Authorized for patients 13-17 years old weighing ≥ 40 kg with severely active Crohn’s disease and patients ≥ 5 years old with moderate to severe active ulcerative colitis.

Learn More

View the Hulio® product monograph.